Publications by authors named "S G Penn"
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
Arthritis Res Ther
July 2024
Background: To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial.
Methods: Patients were randomized to receive upadacitinib 15 mg or 30 mg or MTX. Patients who did not achieve CDAI remission and had < 20% improvement in tender and swollen joint counts at week 26 received rescue therapy (addition of MTX in the upadacitinib group and addition of upadacitinib in the MTX group).
Article Synopsis
- The study evaluated the safety and effectiveness of upadacitinib compared to adalimumab in treating rheumatoid arthritis over a 5-year period, specifically for patients who didn’t respond well to methotrexate.
- Both medications had similar rates of treatment-emergent adverse events, but upadacitinib had slightly higher occurrences of certain side effects, while it also delivered better clinical response rates and lower radiographic progression at the end of the study.
- Overall, upadacitinib showed a favorable benefit-risk profile for long-term use in patients with rheumatoid arthritis, confirming its safety and effectiveness over an extended period.
Article Synopsis
- This study examined the long-term effectiveness and safety of upadacitinib and adalimumab in treating rheumatoid arthritis (RA) patients who were not meeting treatment goals after 228 weeks.
- Patients switched from their initial treatment to the alternate therapy if they had a poor response, and various efficacy measures were tracked over the study period.
- The results showed significant improvements in disease activity for both treatments, with minor advantages for upadacitinib, while safety profiles were generally similar although some adverse events were more common with upadacitinib.
We assessed the effects of supplementing milk fat globules (MFG) on the growth and development of the skeleton in rats fed a Western unbalanced diet (UBD). The UBD is high in sugar and fat, low in protein, fiber, and micronutrients, and negatively impacts health. The MFG-a complex lipid-protein assembly secreted into milk-has a unique structure and composition, which differs significantly from isolated and processed dietary ingredients.
View Article and Find Full Text PDF